| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2012: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2011: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2010: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Research Abstract |
To develop neuroprotective therapy, we investigated the pathogeneisis of acute and subacute encephalitis/encephalopathy by measurements of cerebrospinal fluid (CSF) biomarkers in combination with conventional neuropathological analysis. The results suggest that CSF tau protein and 8-hydroxy-2’deoxyguanosine could be useful in following the clinical course and monitoring the efficacy of therapies. In addition, the use of patient serum for immunohistochemistry is a sensitive screening method for the detection of anti-neuronal autoantibodies in autoimmune encephalitis.
|
